Charles Schwab’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $32M | Buy |
1,244,955
+37,556
| +3% | +$772K | ﹤0.01% | 1530 |
|
|
2026
Q1 | $23.2M | Buy |
1,207,399
+6,924
| +0.6% | +$138K | ﹤0.01% | 1661 |
|
|
2025
Q4 | $19.8M | Buy |
1,200,475
+49,091
| +4% | +$829K | ﹤0.01% | 1754 |
|
|
2025
Q3 | $16.7M | Buy |
1,151,384
+95,365
| +9% | +$1.37M | ﹤0.01% | 1853 |
|
|
2025
Q2 | $14.8M | Buy |
1,056,019
+46,123
| +5% | +$649K | ﹤0.01% | 1825 |
|
|
2025
Q1 | $13.7M | Sell |
1,009,896
-18,566
| -2% | -$356K | ﹤0.01% | 1808 |
|
|
2024
Q4 | $21M | Buy |
1,028,462
+12,652
| +1% | +$324K | ﹤0.01% | 1676 |
|
|
2024
Q3 | $29.6M | Sell |
1,015,810
-43,494
| -4% | -$1.08M | 0.01% | 1466 |
|
|
2024
Q2 | $24.6M | Buy |
1,059,304
+18,245
| +2% | +$350K | ﹤0.01% | 1538 |
|
|
2024
Q1 | $21.4M | Buy |
1,041,059
+34,062
| +3% | +$640K | ﹤0.01% | 1572 |
|
|
2023
Q4 | $21.6M | Buy |
1,006,997
+25,938
| +3% | +$514K | 0.01% | 1553 |
|
|
2023
Q3 | $20.2M | Buy |
981,059
+113,428
| +13% | +$2.88M | 0.01% | 1507 |
|
|
2023
Q2 | $25.6M | Buy |
867,631
+31,303
| +4% | +$880K | 0.01% | 1315 |
|
|
2023
Q1 | $19.3M | Sell |
836,328
-345
| -0% | -$9.49K | 0.01% | 1504 |
|
|
2022
Q4 | $23.3M | Buy |
836,673
+105,793
| +14% | +$3.15M | 0.01% | 1332 |
|
|
2022
Q3 | $22.4M | Sell |
730,880
-642
| -0.1% | -$20.9K | 0.01% | 1285 |
|
|
2022
Q2 | $21.5M | Buy |
731,522
+27,271
| +4% | +$714K | 0.01% | 1355 |
|
|
2022
Q1 | $22.7M | Sell |
704,251
-12,939
| -2% | -$445K | 0.01% | 1443 |
|
|
2021
Q4 | $32M | Buy |
717,190
+13,438
| +2% | +$637K | 0.01% | 1216 |
|
|
2021
Q3 | $35.5M | Buy |
703,752
+63,518
| +10% | +$3.58M | 0.01% | 1099 |
|
|
2021
Q2 | $50.2M | Buy |
640,234
+74,718
| +13% | +$4.62M | 0.02% | 865 |
|
|
2021
Q1 | $32.3M | Buy |
565,516
+72,318
| +15% | +$4.84M | 0.01% | 1133 |
|
|
2020
Q4 | $41.3M | Buy |
493,198
+6,758
| +1% | +$409K | 0.02% | 896 |
|
|
2020
Q3 | $17.4M | Buy |
486,440
+15,194
| +3% | +$458K | 0.01% | 1301 |
|
|
2020
Q2 | $11.4M | Buy |
471,246
+52,574
| +13% | +$1.24M | 0.01% | 1564 |
|
|
2020
Q1 | $7.33M | Buy |
418,672
+44,194
| +12% | +$922K | ﹤0.01% | 1634 |
|
|
2019
Q4 | $6.52M | Buy |
374,478
+7,203
| +2% | +$120K | ﹤0.01% | 1888 |
|
|
2019
Q3 | $5.63M | Buy |
367,275
+14,153
| +4% | +$270K | ﹤0.01% | 1906 |
|
|
2019
Q2 | $7.33M | Buy |
353,122
+14,475
| +4% | +$324K | ﹤0.01% | 1779 |
|
|
2019
Q1 | $7.86M | Buy |
338,647
+16,383
| +5% | +$343K | 0.01% | 1733 |
|
|
2018
Q4 | $6.66M | Sell |
322,264
-2,577
| -0.8% | -$46.7K | 0.01% | 1726 |
|
|
2018
Q3 | $7.06M | Buy |
324,841
+245,312
| +308% | +$4.06M | ﹤0.01% | 1858 |
|
|
2018
Q2 | $1.21M | Buy |
79,529
+13,323
| +20% | +$251K | ﹤0.01% | 2526 |
|
|
2018
Q1 | $1.3M | Buy |
+66,206
| New | +$1.36M | ﹤0.01% | 2444 |
|
Other funds holding DNLI
Charles Schwab's DNLI Position: Q2 2026 in Review
Charles Schwab increased its Denali Therapeutics (DNLI) stake by 3.1% in Q2 2026, buying an estimated $772K and bringing the position to 1,244,955 shares worth $32M. The position accounts for ﹤0.01% of the portfolio, ranked #1530.
Charles Schwab first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $50.2M in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Charles Schwab held 1,244,955 shares of Denali Therapeutics worth $32M as of Q2 2026.
- Charles Schwab bought 37,556 Denali Therapeutics shares in Q2 2026, an estimated $772K.
- Denali Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1530 holding.
- Charles Schwab first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Charles Schwab's Denali Therapeutics position peaked at $50.2M in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.